Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Downgraded to Hold Rating by Zacks Research

Zacks Research downgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a strong-buy rating to a hold rating in a research report released on Monday morning,Zacks.com reports.

Other research analysts have also issued research reports about the stock. DZ Bank lowered shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research note on Wednesday, February 18th. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY opened at $12.36 on Monday. The firm has a market capitalization of $48.57 billion, a PE ratio of -137.32, a P/E/G ratio of 4.96 and a beta of 0.68. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10. The firm has a 50-day moving average price of $12.26 and a 200 day moving average price of $9.72. Bayer Aktiengesellschaft has a 52-week low of $5.30 and a 52-week high of $14.85.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.